Who are Atrasentan low dose group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): "Nefecon®","Ambrisentan", Tracleer®, ERA as specific PAH treatment, EFI/ACT-385781A, Macitentan/Tadalafil FDC, Bosentan and Sildenafil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atrasentan-low-dose-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Atrasentan low dose group — Competitive Intelligence Brief

Atrasentan low dose group (Atrasentan low dose group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist. Area: Cardiovascular.

phase 2 Endothelin receptor antagonist Endothelin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Atrasentan low dose group (Atrasentan low dose group) — AbbVie (prior sponsor, Abbott). Endothelin receptor antagonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Atrasentan low dose group TARGET	Atrasentan low dose group	AbbVie (prior sponsor, Abbott)	phase 2	Endothelin receptor antagonist	Endothelin receptor
"Nefecon®","Ambrisentan"	"Nefecon®","Ambrisentan"	The First Hospital of Jilin University	marketed	Endothelin receptor antagonist (ERA)	Endothelin receptor type A (ETA)
Tracleer®	Tracleer®	Actelion	marketed	Endothelin receptor antagonist	Endothelin receptor A (ETA) and Endothelin receptor B (ETB)
ERA as specific PAH treatment	ERA as specific PAH treatment	Eli Lilly and Company	phase 3	Endothelin receptor antagonist	Endothelin receptor (ETA/ETB)
EFI/ACT-385781A	EFI/ACT-385781A	Actelion	phase 3	Selective endothelin receptor antagonist	Endothelin receptor (ETA/ETB)
Macitentan/Tadalafil FDC	Macitentan/Tadalafil FDC	Actelion	phase 3	Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination	Endothelin receptor A and B / Phosphodiesterase-5
Bosentan and Sildenafil	Bosentan and Sildenafil	Rigshospitalet, Denmark	phase 3	Endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination	Endothelin receptors (ETA/ETB) and phosphodiesterase-5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist class)

AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Actelion · 2 drugs in this class
Bayer · 1 drug in this class
Dr Sudarshan Rajagopal · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Elpen Pharmaceutical Co. Inc. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atrasentan low dose group — Competitive Intelligence Brief. https://druglandscape.com/ci/atrasentan-low-dose-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab